Table 1.
Patient Characteristics.
| Pathologic Features | UCSD | Pure UC | P Value |
|---|---|---|---|
| No. of patients, n (%) | 20 (19.8) | 81 (80.2) | |
| Age, median (IQR) | 67 (64–73) | 69 (63–75) | .511 |
| Sex, n (%) | .391 | ||
| Male | 13 (65.0) | 62 (76.5) | |
| Female | 7 (35.0) | 19 (23.5) | |
| Performance status (ECOG), n (%) | .175 | ||
| 0 | 11 (55.0) | 59 (72.8) | |
| ≥1 | 9 (45.0) | 22 (27.2) | |
| ACCI score, median (IQR) | 4 (3-5) | 3 (3-4) | .177 |
| Clinical T stage, n (%) | .074 | ||
| T2 | 8 (40.0) | 52 (64.2) | |
| ≥T3 | 12 (60.0) | 29 (35.8) | |
| Hydronephrosis, n (%) | 5 (25.0) | 18 (22.2) | .772 |
| Carcinoma in situ, n (%) | 4 (20.0) | 21 (25.9) | .774 |
| Multifocality, n (%) | 9 (45.0) | 50 (61.7) | .209 |
| NLR, median (IQR) | 3.08 (2.05–4.09) | 2.27 (1.80–2.88) | .038 |
| CRP (mg/dL), median (IQR) | 0.40 (0.14–0.65) | 0.12 (0.06–0.47) | .012 |
| Hemoglobin (g/dL), median (IQR) | 12.4 (9.6–13.1) | 12.7 (11.4–13.9) | .177 |
| Neoadjuvant chemotherapy, n (%) | .058 | ||
| MVAC | 2 (22.2) | 18 (62.1) | |
| GC | 7 (77.8) | 11 (37.9) | |
| Pathologic T stage, n (%) | .020 | ||
| ≤T2 | 8 (40.0) | 56 (69.1) | |
| ≥T3 | 12 (60.0) | 25 (30.9) | |
| Pathologic N stage, n (%) | .044 | ||
| Negative | 11 (55.0) | 64 (79.0) | |
| Positive | 9 (45.0) | 17 (21.0) | |
| Lymphovascular invasion, n (%) | 14 (70.0) | 36 (44.4) | .048 |
| No. of lymph node removed (IQR) | 9 (6–13) | 8 (6–13) | .710 |
| Adjuvant chemotherapy, n (%) | 1.00 | ||
| MVAC | 2 (50.0) | 10 (50.0) | |
| GC | 2 (50.0) | 8 (40.0) | |
| PG | 0 (0.0) | 2 (10.0) |
Abbreviations: ACCI, age-adjusted Charlson comorbidity index; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; GC, gemcitabine, cisplatin; IQR, interquartile range; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NLR, neutrophil to lymphocyte ratio; PG, paclitaxel, gemcitabine; UC, urothelial carcinoma; UCSD, urothelial carcinoma with squamous differentiation.